FI941723A7 - Lipofiilisen oligosakkaridin antibiootin suolaa sisältävät seokset - Google Patents

Lipofiilisen oligosakkaridin antibiootin suolaa sisältävät seokset Download PDF

Info

Publication number
FI941723A7
FI941723A7 FI941723A FI941723A FI941723A7 FI 941723 A7 FI941723 A7 FI 941723A7 FI 941723 A FI941723 A FI 941723A FI 941723 A FI941723 A FI 941723A FI 941723 A7 FI941723 A7 FI 941723A7
Authority
FI
Finland
Prior art keywords
containing mixtures
lipophilic oligosaccharide
antibiotic salt
oligosaccharide antibiotic
lipophilic
Prior art date
Application number
FI941723A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI941723A0 (fi
Inventor
Mahesh Patel
Vincent P Gullo
Roberta Hare
David Loebenberg
James B Morton
George H Miller
Heewon Y Kwon
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI941723A0 publication Critical patent/FI941723A0/fi
Publication of FI941723A7 publication Critical patent/FI941723A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
FI941723A 1991-10-16 1994-04-14 Lipofiilisen oligosakkaridin antibiootin suolaa sisältävät seokset FI941723A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77786491A 1991-10-16 1991-10-16
PCT/US1992/008565 WO1993007904A1 (en) 1991-10-16 1992-10-14 Lipophilic oligosaccharide antibiotic salt compositions

Publications (2)

Publication Number Publication Date
FI941723A0 FI941723A0 (fi) 1994-04-14
FI941723A7 true FI941723A7 (fi) 1994-04-14

Family

ID=25111545

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941723A FI941723A7 (fi) 1991-10-16 1994-04-14 Lipofiilisen oligosakkaridin antibiootin suolaa sisältävät seokset

Country Status (27)

Country Link
US (1) US5624914A (enExample)
EP (2) EP0610295A1 (enExample)
JP (1) JP2614407B2 (enExample)
KR (1) KR100249584B1 (enExample)
CN (1) CN1035923C (enExample)
AT (1) ATE156019T1 (enExample)
AU (1) AU678344B2 (enExample)
CA (1) CA2121345C (enExample)
DE (1) DE69221252T2 (enExample)
DK (1) DK0538011T3 (enExample)
ES (1) ES2104845T3 (enExample)
FI (1) FI941723A7 (enExample)
GR (1) GR3024800T3 (enExample)
HK (1) HK1001085A1 (enExample)
HR (1) HRP921069B1 (enExample)
HU (1) HUT75157A (enExample)
IL (1) IL103446A (enExample)
MX (1) MX9205922A (enExample)
NO (1) NO307326B1 (enExample)
NZ (1) NZ244735A (enExample)
PH (1) PH31675A (enExample)
PL (1) PL170591B1 (enExample)
SI (1) SI9200260A (enExample)
TW (1) TW221378B (enExample)
WO (1) WO1993007904A1 (enExample)
YU (1) YU48722B (enExample)
ZA (1) ZA927923B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380172B1 (en) 1991-10-16 2002-04-30 Schering Corporation Monomeric lipophilic oligosaccharide antibiotic compositions
US5948688A (en) * 1991-10-16 1999-09-07 Schering Corporation Method of determining monomeric drug content
US5652226A (en) * 1995-12-22 1997-07-29 Schering Corporation Water soluble antibiotics
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US5763600A (en) * 1997-04-18 1998-06-09 Schering Corporation Oligosaccharide antibiotics and process for preparation thereof
JP2001518556A (ja) * 1997-10-03 2001-10-16 ガレニカ ファーマシューティカルズ, インコーポレイテッド イミン形成ポリサッカライド、その調製、ならびにアジュバントおよび免疫刺激剤としてのその使用
US6162910A (en) * 1998-11-30 2000-12-19 Schering Corporation Process for preparing lipophilic oligosaccharide antibiotics
US6320044B1 (en) 1998-12-18 2001-11-20 Schering Corporation Process for recovering lipophilic oligosaccharide antibiotics
CO5231233A1 (es) * 1998-12-18 2002-12-27 Cherinf Corp Proceso para recuperar antibioticos oligosacaridos lipofilic lipofilicos
WO2001039573A2 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von lungensurfactant zur behandlung von legionärskrankheit
US6861513B2 (en) 2000-01-12 2005-03-01 Schering Corporation Everninomicin biosynthetic genes
DE60136926D1 (de) * 2000-05-02 2009-01-22 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
WO2002032459A2 (en) * 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
DE10109166A1 (de) * 2001-02-25 2002-09-12 Combinature Biopharm Ag Avilamycin-Derivate
EP1730163A4 (en) * 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
EP1666228B1 (en) * 2004-12-01 2016-04-13 Nitto Denko Corporation Foam filling member
BRPI0610668A2 (pt) * 2005-04-12 2010-07-13 Panacos Pharmaceuticals Inc polimorfas de di-n-metil-d-glucamina do ácido 3-o-(3',3'-dimetilsuccinil) betulìnico
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
JP2010095454A (ja) * 2008-10-14 2010-04-30 Cyclochem:Kk 抗菌組成物
EP4324483A3 (en) * 2011-01-14 2024-05-01 Emory University Oligosaccharide conjugates for targeting bacteria and uses related thereto
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN106317143B (zh) * 2016-08-23 2020-10-30 河北圣雪大成制药有限责任公司 一种提取阿维拉霉素的方法
JP2025506676A (ja) 2022-02-18 2025-03-13 ベレン セラピューティクス ピー.ビー.シー. ヒドロキシプロピル-ベータ-シクロデキストリンの組成物及びその精製方法
CN117024611B (zh) * 2023-03-01 2024-05-17 中国科学院南海海洋研究所 寡糖类抗生素everninomicin高产菌株的构建及活性的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR128F (enExample) * 1962-04-02
US3915956A (en) * 1973-07-09 1975-10-28 Schering Corp Reduction products of everninomicins and methods for their manufacture
US3920629A (en) * 1973-09-19 1975-11-18 Schering Corp Desevernitrose everninomicins and method for their manufacture
US4006225A (en) * 1973-10-31 1977-02-01 Schering Corporation Method of using reduction products of everninomicins as antibacterial agents and pharmaceutical compositions useful therefor
US4027016A (en) * 1976-01-19 1977-05-31 Schering Corporation Everninomicin antibacterial derivatives, electrochemical method for their manufacture, method for their use as antibacterial agents, and pharmaceutical compositions useful therefor
US3998708A (en) * 1976-01-19 1976-12-21 Schering Corporation Electrochemical process for preparing hydroxylaminoeverninomicins
US4129720A (en) * 1977-02-14 1978-12-12 Schering Corporation Aminoeverninomicin and derivatives thereof
US4597968A (en) * 1982-08-06 1986-07-01 Schering Corporation Antibiotic 13-384 complex from Micromonospora carbonacea var africana
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4735903A (en) * 1984-06-21 1988-04-05 Schering Corporation Micromonospora carbonacea var africana
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
US4767748A (en) * 1985-10-15 1988-07-30 Schering Corporation Substituted oligosaccharide antibodies
US4622314A (en) * 1985-10-15 1986-11-11 Schering Corporation Substituted oligosaccharide antibiotics
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도

Also Published As

Publication number Publication date
YU48722B (sh) 1999-07-28
CN1035923C (zh) 1997-09-24
MX9205922A (es) 1994-08-31
CN1073359A (zh) 1993-06-23
EP0538011A1 (en) 1993-04-21
NO941276D0 (no) 1994-04-08
HRP921069A2 (en) 1994-12-31
DK0538011T3 (da) 1997-09-08
AU678344B2 (en) 1997-05-29
IL103446A (en) 1997-02-18
IL103446A0 (en) 1993-03-15
CA2121345C (en) 1998-08-25
ES2104845T3 (es) 1997-10-16
ZA927923B (en) 1993-04-26
HK1001085A1 (en) 1998-05-22
HU9401104D0 (en) 1994-07-28
AU2780692A (en) 1993-05-21
EP0538011B1 (en) 1997-07-30
EP0610295A1 (en) 1994-08-17
JP2614407B2 (ja) 1997-05-28
GR3024800T3 (en) 1998-01-30
TW221378B (enExample) 1994-03-01
DE69221252D1 (de) 1997-09-04
HRP921069B1 (en) 1999-12-31
PL170591B1 (pl) 1997-01-31
PH31675A (en) 1999-01-18
SI9200260A (en) 1993-06-30
NO941276L (no) 1994-04-08
US5624914A (en) 1997-04-29
HUT75157A (en) 1997-04-28
NO307326B1 (no) 2000-03-20
KR100249584B1 (ko) 2000-04-01
YU92192A (sr) 1996-01-09
ATE156019T1 (de) 1997-08-15
JPH06510546A (ja) 1994-11-24
DE69221252T2 (de) 1998-01-22
FI941723A0 (fi) 1994-04-14
CA2121345A1 (en) 1993-04-29
WO1993007904A1 (en) 1993-04-29
NZ244735A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
DE69208877D1 (de) Chinuclidinderivate
FI924160A7 (fi) Benzanilidderivat
FI935726A7 (fi) Atsanorbornaanijohdannaisia
NO922182D0 (no) Krystallinske oksatiolan-derivater
DE69212948D1 (de) Styrol-Derivate
FI924787A7 (fi) Sakkaridimatriisi
FI952980L (fi) Annostelumekanismi
NO932670D0 (no) Blandinger
FI925422L (fi) Indolopyrrolokarbazolderivat
FI925763L (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
FI923726L (fi) Sulfaterade glykosaminoglykanoidderivat
FI934842L (fi) Katjoniska polysackarider
DE69228128D1 (de) Glycosphingolipide
FI935243L (fi) Pyridonkarboxylsyraderivat
FI923342L (fi) Pleuromutilinkomplex
FI920563A7 (fi) Pyridiiniyhdisteitä
DE69122860D1 (de) Multiplexer
FI920394A7 (fi) 3-kinuklidiinijohdannaiset
FI924145L (fi) 3-cykloalkylprop-2-enamidderivat
FI935293A7 (fi) Propensyraderivat
FI925317A0 (fi) Makrocykliska laktamderivat
FI942070A7 (fi) Nitroksialkyyliamidijohdannaiset
FI933346A7 (fi) Aminoalkylpyrrolidinyltiokarbapenemderivat
FI921836L (fi) Folieutdelningsanordning
KR930702353A (ko) 2- 카르바페넴 유도체